Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-02-21

Clinical Trial Update: Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update investigating risk of hypoglycemia with sitagliptin in type 2 diabetes patients; results completed and posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sitagliptin (sitagliptin)

Snippet

Sponsor: Profil Institut für Stoffwechselforschung GmbH | Conditions: Pharmacological Action | Phase 2 | Status: COMPLETED | Results posted: 2021-02-21